NCT03652441

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: University of Cologne · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the experimental consolidative treatment strategy. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

Conditions

• Classical Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Brentuximab Vedotin	BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions

Timeline

• Start date: 2019-11-13
• Primary completion: 2023-08-10
• Completion: 2025-01-25
• First posted: 2018-08-29
• Last updated: 2026-03-05

Locations

1 site across 1 country: Germany